Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539575 · ClinicalTrials.gov registry record · NA
CB1R in Synthetic Psychoactive Cannabinoids
A NA study of Drug Dependence, sponsored by Yale University.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03539575: Active NA study of Drug Dependence, sponsored by Yale University.
NCT03539575 is a NA study of Drug Dependence that is active but no longer recruiting, run by Yale University. The registered enrollment target is 15 participants, below the 304-participant average among 9 other Drug Dependence trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03539575, a NA study of Drug Dependence, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.
Primary Outcome
CB1R availability using \[11-C\]OMAR PET imaging Change in CB1R availability (e.g. volume distribution).
Conditions Studied
Interventions
- OTHER [11-C]OMAR
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT03539575 still lists
NCT03539575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 304-participant average among 9 other Drug Dependence trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Drug Dependence appearing as the primary indexed condition, and to 1 intervention - of which [11-C]OMAR is the first listed.
NCT03539575 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03539575 about?
NCT03539575 is a clinical study titled "CB1R in Synthetic Psychoactive Cannabinoids". The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.
What is the current status of trial NCT03539575?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2018-05-01. Estimated completion is 2025-12.
What conditions does trial NCT03539575 study?
This clinical trial studies the following conditions: Drug Dependence.
What interventions are being tested in trial NCT03539575?
The interventions under investigation include: [11-C]OMAR (OTHER).
Who is sponsoring clinical trial NCT03539575?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539575 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03539575's enrollment target sits among peer trials
15 9th of 9 higher than 1 of 9 other Drug Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Drug Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders
COMPLETED · NA
-
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
COMPLETED · NA
-
Innovative Digital Therapeutic for Smoking Cessation
COMPLETED · NA
-
Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use
COMPLETED · Phase 3
-
Drug Discrimination in Methadone-Maintained Humans Study 3
COMPLETED · Phase 1
-
The Effect of Fetal Gender on Maternal Substance Abuse Treatment
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI